Compare Citius Pharmaceuticals Inc (CTXR) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Qurate Retail Inc Series A — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Qurate Retail Inc Series A trades at $0.09 (market cap $1.05M). The key difference: Citius Pharmaceuticals Inc is far larger — about 13.9× Qurate Retail Inc Series A's market cap. Which is the better fit depends on your goals.
| CTXR | QVCAQ | |
|---|---|---|
Market Cap | $14.64M | $1.05M |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $15.03 |
52-Week Low | $0.53 | $0.07 |
Enterprise Value | $10.86M | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
QVCAQ trades at $0.082, down 9.99% today, with a bearish technical outlook showing 13 sell signals versus 3 buy signals. Fundamentally, the company reported a net loss of $2.44 billion in 2025 on $9.23 billion revenue, with negative shareholder equity of $971 million and concerning debt-to-asset ratio of 77.57%. Recent earnings show volatility with one beat and three misses in the last four quarters.
The stock faces significant headwinds from persistent losses, negative equity, and high leverage. While QVC's recent brand celebration shows ongoing operations, the financial deterioration and bearish technical indicators suggest caution. Recovery depends on sustainable profitability improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
